News | July 16, 2012

Preliminary Data Shows Delivery of Dexamethasone via Micro-Infusion Catheter Inhibits Restenosis

Dexamethasone, an anti-inflammatory medication, infused into the inflamed tissue around lesions via the Mercator Bullfrog catheter enhances efficacy after femoropopliteal revascularization

July 16, 2012 —  Mercator MedSystems, a medical technology company whose platform Micro-Infusion Catheter technology announced preliminary results of its DANCE clinical trial that continues to follow patients at the University of California, San Francisco (UCSF) and  San Francisco VA Medical Center. The technology offers catheter-guided, microfluid injection systems for site-specific, nonsystemic delivery of therapeutic agents directly across any peripheral or coronary blood vessel to treat peripheral vascular diseases, cancer, heart attacks, and other life-threatening diseases and disorders.

The sponsor and principal investigator of the DANCE clinical trial is Christopher D. Owens, M.D., an associate professor and vascular surgeon at the Center for Limb Preservation, part of the UCSF Heart and Vascular Center. Results on 10 patients to date, at nine-month follow-up after an angioplasty or atherectomy, showed that those patients who also were infused with dexamethasone to the adventitia of the targeted blood vessel made possible by Mercator MedSystems’ patented and U.S. Food and Drug Administration (FDA)-cleared Bullfrog Micro-Infusion Catheter have now passed nine months without restenosis of the index lesion. The Mercator platform is the first and only vascular-access system designed to inject drugs, genes and cells safely through vessel walls into deep tissues without major surgery.

Delivering drugs through the blood vessel wall into the perivascular space and adventitia allows for direct, highly controllable and concentrated treatment, not only minimizing the toxicity of systemic administration but also avoiding the “washing away” of drug into the bloodstream. This can reduce drug side effects, increase therapeutic effectiveness, decrease the cost of medical treatment and improve patient quality of life.

Mercator MedSystems Inc., based in San Leandro, Calif., is a privately held medical technology company focused on commercializing catheter-guided, microfluid infusion systems for site-specific delivery of therapeutic agents for applications in hypertension, cardiovascular disease, pulmonary, oncology and regenerative medicine.

For more information: www.mercatormed.com

Related Content

Reflow Medical's Wingman Crossing Catheter Receives FDA Clearance for Coronary Indication
News | Catheters | October 02, 2017
October 2, 2017 — Reflow Medical Inc. announced that the company has received 510(k) clearance from the U.S.
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters | August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
Teleflex, FDA 510k clearance, TrapLiner Catheter, U.S. launch
Technology | Catheters | March 02, 2017
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
Merit Medical Systems, SwiftNINJA Steerable Microcatheter, FDA 510(k) clearance
Technology | Catheters | November 09, 2016
November 9, 2016 — Merit Medical Systems Inc.
VentureMed Group, Flex Scoring Catheter, FDA approval, peripheral arterial disease, PAD, endovascular treatment
Technology | Catheters | July 13, 2016
July 13, 2016 — VentureMed Group Ltd., specializing in devices for the endovascular treatment of...
Roxwood Medical, MicroCross Catheter, full U.S. launch

Image courtesy of Roxwood Medical

Technology | Catheters | January 07, 2016
Roxwood Medical Inc. reported that more than 500 patients have been successfully treated as part of the initial limited...
Overlay Init